心脏生成细胞疗法治疗晚期缺血性心力衰竭:前瞻性随机双盲假手术对照CHART-1临床试验39周结果
CHART-1试验在39家医院纳入348例接受骨髓采集的缺血性心力衰竭患者,315例随机接受心脏生成细胞心内膜内注射(157例)或假手术(158例)。39周主要复合终点为中性(Mann-Whitney估计值0.54,95%CI 0.47-0.61,P=0.27),探索性分析提示基线左室舒张末期容积200-370 mL患者可能获益。
要点
- 39周主要复合终点为中性(Mann-Whitney估计值0.54,95%CI 0.47-0.61,P=0.27)。
- 探索性分析提示基线左室舒张末期容积200-370 mL患者可能从细胞治疗获益。
- 严重不良事件无差异;心脏生成细胞组1例(0.9%)与假手术组9例(5.4%)发生流产或心脏性猝死。
核心结论
- 主要终点为中性,全队列安全性得到证实;作者认为对舒张末期容积升高的患者进一步评估心脏生成细胞治疗是必要的。
研究设计与样本
- 多国、随机、双盲、假手术对照研究,在39家医院开展。
- 随机分为心脏生成细胞经 retention-enhanced 导管心内膜内注射组(n=157)或假手术组(n=158);271例按随机方案实施手术(心脏生成细胞组n=120,假手术组n=151)。
主要发现
- 主要疗效终点为39周Finkelstein-Schoenfeld分层复合终点(全因死亡、心力衰竭恶化、明尼苏达心力衰竭生活质量问卷评分、6分钟步行距离、左室收缩末期容积和射血分数)。
- 主要结局为中性(Mann-Whitney估计值0.54,95%CI 0.47-0.61,P=0.27,值>0.5 favour 细胞治疗)。
- 探索性分析提示基线左室舒张末期容积200-370 mL患者(占60%)的细胞治疗对主要复合终点有获益(Mann-Whitney估计值0.61,95%CI 0.52-0.70,P=0.015)。
- 严重不良事件无差异;心脏生成细胞组1例(0.9%)与假手术组9例(5.4%)发生流产或心脏性猝死。
关键数值与推荐
- 主要终点:39周Finkelstein-Schoenfeld分层复合终点,Mann-Whitney估计值0.54(95%CI 0.47-0.61,P=0.27)。
- 探索性分析:基线左室舒张末期容积200-370 mL患者,Mann-Whitney估计值0.61(95%CI 0.52-0.70,P=0.015)。
临床怎么用
- 作者认为对舒张末期容积升高的患者进一步评估心脏生成细胞治疗是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. METHODS AND RESULTS: This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein-Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann-Whitney estimator 0.54, 95% confidence interval [CI] 0.47-0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients) (Mann-Whitney estimator 0.61, 95% CI 0.52-0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. CONCLUSION: The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.
引用
- Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017. PMID: 28025189. doi:10.1093/eurheartj/ehw543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。